Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to demonstrate that intravenous iron oligosaccharide is
non-inferior to oral iron sulphate in reducing iron deficiency anaemia secondary to
inflammatory bowel disease (IBD), evaluated as the ability to increase haemoglobin (Hb).